Alliance Director. Each Party shall appoint one person to be its point of contact with responsibility for facilitating communication and collaboration between the Parties (each, an “Alliance Director”). The Alliance Directors shall be permanent participants of the JRC meetings (but not members of the JRC) and may attend JOT meetings as appropriate. The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the JRC to reach consensus and avert escalation of such issues or potential disputes.
Alliance Director. Each Party shall appoint one person to be the point of contact within each Party with responsibility for facilitating communication and collaboration between the Parties (each, an “Alliance Director”). The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the applicable steering committee to reach consensus and avert escalation of such issues or potential disputes.
Alliance Director. Each Party shall appoint one person to be its point of contact with responsibility for facilitating communication and collaboration between the Parties (each, an “Alliance Director”). The Alliance Directors shall be permanent participants of the JOC meetings (but not Members of the JOC). The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the JOC to reach consensus and avert escalation of such issues or potential disputes.
Alliance Director. Each Party shall appoint an Alliance Director. The Alliance Directors shall be the point of contact within each Party with responsibility for facilitating communication and collaboration between the Parties. The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the JSC to reach consensus and avert escalation of such issues or potential disputes.
Alliance Director. PTC, Roche and the Foundation shall each appoint an Alliance Director. The Alliance Directors shall be the point of contact within each Party and the Foundation with responsibility for facilitating communication and collaboration between PTC, Roche and the Foundation. They are permanent participants of the JSC meetings and may attend JOT meetings as appropriate. The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the JSC to reach consensus and avert escalation of such issues or potential disputes.
Alliance Director. Each of Tempus and GSK shall appoint an alliance director (each, an “Alliance Director”) to act as the principal point of contact between the Parties on all matters relating to the Activities and to facilitate communication between the Parties regarding the Activities. The Alliance Directors shall be appointed within [***] of the Effective Date.
Alliance Director. The Parties shall each designate a representative (an “Alliance Director”) within [***] days after the Closing Date (who may be replaced at any time by providing written notice thereof), who shall have responsibility to (i) facilitate the coordination of the various Committees and Teams under this Agreement, including the JSC, JPC, CT, DT and MT, and any other committees that the Parties mutually agree, in writing, to establish as part of this Agreement, and (ii) report collaboration issues and progress to their management. Each Party will be solely responsible for any and all cost and expenses related to the appointment of an Alliance Director and any and all costs and expenses incurred by its Alliance Director in conducting the activities contemplated under this Agreement.
Alliance Director. Each party will assign an “Alliance Director” to manage and oversee that party’s day-to-day Alliance-related activities, such as business development interface, training coordination, marketing coordination and metrics reporting. Alliance Directors will meet as agreed by the parties, either in person or telephonically, and involve all reasonably necessary personnel of the parties in such meetings. Agendas may include pipeline reviews, the resolution of any escalated issues relating to business development or potential engagements, joint marketing activities, skills building/training initiatives, metrics reporting and new Alliance opportunities. The Alliance Directors will attend meetings of the Alliance Executives at the invitation of the Alliance Executives.
Alliance Director. Each Party shall appoint one person to be its point of contact with responsibility for facilitating communication and collaboration between the Parties (each, an “Alliance Director”). The Alliance Directors shall be permanent participants of the Committee meetings (but not members of the Committee) and may attend JOT meetings as appropriate. The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the Committees to reach consensus and avert potential disputes. The Alliance Director will be the point of contact for communicating regular updates and shall provide such regular updates about Development and Commercialization for Licensed Products except where updates are otherwise handled by the JSC in accordance with this Agreement. Upon Dicerna’s request, the Alliance Director shall discuss and answer Dicerna’s reasonable questions regarding the information received from Roche under Sections 6.4 and 10.3. In the event of a material change to the Development or Commercialization of a Licensed Product, Roche’s Alliance Director shall timely inform Dicerna of such change in accordance with Sections 6.4, 7.10, and 10.3, and to the extent the JSC does not meet to discuss such material change or there is no JSC, Roche’s Alliance Director shall discuss such change with Dicerna and provide further information as may be reasonably requested by Dicerna regarding such change.
Alliance Director. 1.6 Antibody
